undamentalytics Newsletter
Sign in

Corcept Therapeutics Inc income statement

In fiscal 2025, Corcept Therapeutics Inc reported revenue of $761m, up 12.8% on the year before, operating income of $44.8m (a 5.9% margin) and net income of $99.7m, or $0.82 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue081159251306354366402482675761831
Cost of revenue—24566556111314
Gross profit—79156246301348361396476664748817
Research and development1424407589115114131184247255254
Selling, general and administrative—456281100105122153184280449556
General and administrative6———————————
Operating income−20105389112128124113107137456
Income before tax—853921171321251161251616626
Income tax—0−7617222612151820−33−29
Net income−208129759410611310110614110055
Diluted EPS−$0.38$0.07$1.04$0.60$0.77$0.85$0.89$0.87$0.94$1.23$0.82$0.48
Diluted shares (average)—116m125m127m123m124m126m116m112m113m120m116m
EBITDA−20105390112129126114108138468

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CORT vs SUPNAXSM vs CORTCORT vs PCRX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Corcept Therapeutics Inc's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Corcept Therapeutics Inc.